Ose Pharma International S.A. Stock
Ose Pharma International S.A. dominated the market today, gaining €0.20 (3.620%).
Our community identified positive and negative aspects for Ose Pharma International S.A. stock for the coming years. 0 users see the criterium "EBIT growth" as a plus for the Ose Pharma International S.A. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Ose Pharma International S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
News
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.
Nicolas Poirier, Chief Executive Officer